Table 3.
Protein comparison of uninfected and infected peripheral blood mononuclear cells (PBMC) EVs.
| Protein | Uninfected PBMC 1 | Infected PBMC 1 | Uninfected PBMC 2 | Infected PBMC 2 | Uninfected PBMC 3 | Infected PBMC 3 | |
|---|---|---|---|---|---|---|---|
| Controls | Integrin Alpha-II B Preprotein | +++ | - | +++ | - | +++ | - |
| Sodium/Calcium Exchanger 3 Preprotein | - | ++ | - | ++ | - | ++ | |
| Talin-1 | + | + | + | + | + | + | |
| HSP 90 | ++ | + | ++ | + | ++ | + | |
| RNA Binding Proteins | hnRNP K | + | + | ++ | + | ++ | + |
| hnRNP C1/C2 | + | + | + | + | +++ | - | |
| hnRNP R | + | - | ++ | - | +++ | - | |
| hnRNP Q | + | + | +++ | + | ++ | + | |
| hnRNP U | + | + | + | +++ | + | +++ | |
| hnRNP D0 | ++ | + | +++ | + | +++ | + | |
| Histones | Histone H1 | +++ | - | +++ | + | +++ | + |
| Histone H2A | ++ | + | ++ | + | ++ | + | |
| Histone H2B | + | + | ++ | + | + | + | |
| Histone H3 | ++ | + | +++ | + | +++ | + | |
| Histone H4 | + | + | + | + | +++ | + | |
| Annexins | Annexin A1 | +++ | + | ++ | + | +++ | + |
| Annexin A2 | ++ | + | +++ | + | ++ | - | |
| Annexin A5 | +++ | - | - | - | + | - | |
| Annexin A6 | ++ | + | +++ | + | +++ | + | |
| Misc. Proteins | Proflin | + | + | + | +++ | + | +++ |
| Cofilin | + | + | ++ | + | +++ | + | |
| Elongation Factor 1 | ++ | - | + | + | ++ | - | |
| Elongation Factor 2 | + | + | + | + | ++ | + | |
| Calponin 2 | ++ | - | ++ | - | ++ | - | |
| Cathepsin G | + | - | + | - | - | - | |
| Plectin | + | - | + | - | + | - | |
| 14-3-3 Protein Zeta/Delta | + | ++ | + | + | + | + | |
| Rap-1B | + | ++ | + | + | + | ++ | |
| HSP60 | + | +++ | + | + | + | +++ |
The 6-day old cell supernatants from uninfected PBMCs was harvested and treated with ExoMAX overnight. PBMCs were then infected with HIV-1 89.6 (MOI 10) and placed under cART. 7-day old cell supernatants from the infected PBMCs were harvested and treated with ExoMAX overnight. Mass spectrometry was performed on the EVs. The resulting peptides were identified using Proteome Discoverer software. The table shows differences between the 3 PBMC EVs pre- and post-infection. HSP 90 was used as a control while differences can be seen in RNA binding proteins, histones, annexins, and other proteins. The amount of protein in each type of EV was evaluated semi-quantitatively based on the number of peptide sequences identified. Proteins are denoted as being absent (“-“) or present (“+”). If a protein is increased by 2× in one EV type over the other, then the protein is denoted as enriched (“++”). If a protein is increased by at least 3× in one EV type over the other, then the protein is denoted as significantly enriched (“+++”). Proteins are absent, present, increased 2× over the other, or increased 3× over the other (“-“, “+”, “++”, “+++”), respectively.